Talfirastide: Difference between revisions
Content deleted Content added
←Created page with ''''Talfirastide''' (development name '''TXA127''') is an experimental synthetic analog of angiotensin (1-7)<ref>{{cite journal |display-authors=2 |last1=Wagener |first1=Gebhard |last2=Goldklang |first2=Monica P. |last3=Gerber |first3=Adam |last4=Elisman |first4=Katerina |last5=Eiseman |first5=Katherine A. |last6=Fonseca |first6=Laura D. |last7=D’Armiento |first7=Jeanine M. |title=A randomized, placebo-controlled, double-blinded pilot study of angioten...' |
(No difference)
|
Revision as of 06:40, 7 December 2023
Talfirastide (development name TXA127) is an experimental synthetic analog of angiotensin (1-7)[1] that works as an angiotensin II type 1 receptor–biased ligand. It has been tested in people with COVID-19[2] and stroke.[3]
References
- ^ Wagener, Gebhard; Goldklang, Monica P.; et al. (28 July 2022). "A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19". Critical Care. 26: 229. doi:10.1186/s13054-022-04096-9. ISSN 1364-8535.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Self, Wesley H.; Shotwell, Matthew S.; et al. (11 April 2023). "Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials". JAMA. 329 (14): 1170. doi:10.1001/jama.2023.3546.
- ^ "Phase 2 Study of TXA127 in Post-ischemic Stroke Patients - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 7 December 2023.